EBS compared with LLY: revenue, margins and what each company keeps, and the suppliers and customers both name

EBSEmergent BioSolutions Inc.

Mkt capRevenueRevenue

LLYELI Lilly & Co

Mkt capRevenueRevenue

Compare

EBSEmergent BioSolutions Inc.

LLYELI Lilly & Co

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

EBS

2 of 4at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±19.1%▼−2.95%×0.16

Q2 FY26±14.3%▼−29.58%×2.07

Q1 FY26±17.3%▲+2.92%×0.17

Feb 27 '26±23.5%▼−26.58%×1.13

LLY

3 of 4at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±5.1%▲+6.63%×1.29

Q2 FY26±6.2%▲+4.86%×0.79

= impliedEBS realized, solidLLY realized, hatchedOne scale, both sides: full bar = 30%× = |realized| ÷ impliedSource: market data

Q1 FY26

±5.3%

▲+9.80%

×1.85

Feb 4 '26±6.1%▲+10.33%×1.69

EBSEmergent BioSolutions Inc.

6.03▲+3.07%· post 6.03

Mkt cap$311.6MRevenue$110MQ3 FY26Revenue$743MFY25

LLYELI Lilly & Co

1,360.90▼−0.28%· post 1,358.90

ClosedNov 6 '26

Mkt cap$1.2TRevenue$24.4BQ3 FY26Revenue$65.2BFY25

Compare

ClosedNov 6 '26

EBSEmergent BioSolutions Inc.

LLYELI Lilly & Co

6.03▲+3.07%post 6.03

Price

1,360.90▼−0.28%post 1,358.90

$311.6M

Mkt cap

$1.2T

Q3 FY26$110M

Revenue

$24.4BQ3 FY26

FY25$743M

Revenue

$65.2BFY25

EBS6.03▲+3.07%vsLLY1,360.90▼−0.28%ClosedNov 6 '26